Literature DB >> 21931468

Personalized medicine: identifying the appropriate patient through biomarkers in oncology.

.   

Abstract

Entities:  

Year:  2011        PMID： 21931468      PMCID： PMC3171807     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


× No keyword cloud information.
  19 in total

Review 1.  Biomarkers and surrogate endpoints: preferred definitions and conceptual framework.

Authors: 
Journal:  Clin Pharmacol Ther       Date:  2001-03       Impact factor: 6.875

Review 2.  Chemical and pathway proteomics: powerful tools for oncology drug discovery and personalized health care.

Authors:  Ulrich Kruse; Marcus Bantscheff; Gerard Drewes; Carsten Hopf
Journal:  Mol Cell Proteomics       Date:  2008-08-01       Impact factor: 5.911

Review 3.  Cancer screening: the clash of science and intuition.

Authors:  Barnett S Kramer; Jennifer Miller Croswell
Journal:  Annu Rev Med       Date:  2009       Impact factor: 13.739

4.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

Authors:  Antonio C Wolff; M Elizabeth H Hammond; Jared N Schwartz; Karen L Hagerty; D Craig Allred; Richard J Cote; Mitchell Dowsett; Patrick L Fitzgibbons; Wedad M Hanna; Amy Langer; Lisa M McShane; Soonmyung Paik; Mark D Pegram; Edith A Perez; Michael F Press; Anthony Rhodes; Catharine Sturgeon; Sheila E Taube; Raymond Tubbs; Gail H Vance; Marc van de Vijver; Thomas M Wheeler; Daniel F Hayes
Journal:  J Clin Oncol       Date:  2006-12-11       Impact factor: 44.544

Review 5.  Glycomics and disease markers.

Authors:  Hyun Joo An; Scott R Kronewitter; Maria Lorna A de Leoz; Carlito B Lebrilla
Journal:  Curr Opin Chem Biol       Date:  2009-09-21       Impact factor: 8.822

6.  How close is the bench to the bedside? Metabolic profiling in cancer research.

Authors:  Que N Van; Timothy D Veenstra
Journal:  Genome Med       Date:  2009-01-20       Impact factor: 11.117

Review 7.  Proteomics: new technologies and clinical applications.

Authors:  Martin Latterich; Mark Abramovitz; Brian Leyland-Jones
Journal:  Eur J Cancer       Date:  2008-11-01       Impact factor: 9.162

8.  Issues in using progression-free survival when evaluating oncology products.

Authors:  Thomas R Fleming; Mark D Rothmann; Hong Laura Lu
Journal:  J Clin Oncol       Date:  2009-05-04       Impact factor: 44.544

9.  A global view of cancer-specific transcript variants by subtractive transcriptome-wide analysis.

Authors:  Chunjiang He; Fang Zhou; Zhixiang Zuo; Hanhua Cheng; Rongjia Zhou
Journal:  PLoS One       Date:  2009-03-06       Impact factor: 3.240

Review 10.  Emerging technologies for assessing HER2 amplification.

Authors:  Frédérique Penault-Llorca; Michael Bilous; Mitch Dowsett; Wedad Hanna; Robert Yoshiyuki Osamura; Josef Rüschoff; Marc van de Vijver
Journal:  Am J Clin Pathol       Date:  2009-10       Impact factor: 2.493
View more
  3 in total

Review 1.  Neurotheranostics as personalized medicines.

Authors:  Bhavesh D Kevadiya; Brendan M Ottemann; Midhun Ben Thomas; Insiya Mukadam; Saumya Nigam; JoEllyn McMillan; Santhi Gorantla; Tatiana K Bronich; Benson Edagwa; Howard E Gendelman
Journal:  Adv Drug Deliv Rev       Date:  2018-10-26       Impact factor: 15.470

Review 2.  Exploitation of Gene Expression and Cancer Biomarkers in Paving the Path to Era of Personalized Medicine.

Authors:  Hala Fawzy Mohamed Kamel; Hiba Saeed A Bagader Al-Amodi
Journal:  Genomics Proteomics Bioinformatics       Date:  2017-08-13       Impact factor: 7.691

3.  Personalized medicine in cardiovascular diseases.

Authors:  Moo-Sik Lee; Andreas J Flammer; Lilach O Lerman; Amir Lerman
Journal:  Korean Circ J       Date:  2012-09-27       Impact factor: 3.243
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.